ADC Therapeutics SA
ADCT$173M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaEPALINGES263 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Feb 28, 2026
20dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
Loncastuximab Tesirine Phase 3 Results Expected
Feb 28, 2026Loncastuximab Tesirine440
Primary completion for Loncastuximab Tesirine trial (NCT04384484) in Relapsed Diffuse Large B-Cell Lymphoma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Loncastuximab Tesirine
Relapsed Diffuse Large B-Cell Lymphoma
Camidanlumab Tesirine
Relapsed Hodgkin Lymphoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Loncastuximab Tesirine | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma | - |
Camidanlumab Tesirine | Phase 2 | Relapsed Hodgkin Lymphoma | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
ADCT News